AA
FOLD

AlphaCentric Advisors’s Amicus Therapeutics FOLD Stock Holding History

AlphaCentric Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-205,000
Closed -$2.19M – 243
2024
Q3 		$2.19M Buy
205,000
+2,500
+1% +$27.2K 1.63% 16
2024
Q2 		$2.01M Buy
202,500
+27,500
+16% +$282K 1.48% 15
2024
Q1 		$2.06M Buy
175,000
+35,000
+25% +$448K 1.24% 23
2023
Q4 		$1.99M Buy
140,000
+7,500
+6% +$85.2K 1.33% 23
2023
Q3 		$1.61M Hold
132,500
– – 0.91% 37
2023
Q2 		$1.66M Buy
+132,500
New +$1.57M 0.92% 40

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaCentric Advisors's FOLD Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 205,000 shares — an estimated $2.19M sold.

AlphaCentric Advisors first reported a position in FOLD in Q2 2023 and held it in 6 quarters. The position peaked at $2.19M in Q3 2024. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 205,000 Amicus Therapeutics shares in Q4 2024, an estimated $2.19M.
  • AlphaCentric Advisors first reported a position in Amicus Therapeutics in Q2 2023 and held it in 6 quarters.
  • AlphaCentric Advisors's Amicus Therapeutics position peaked at $2.19M in Q3 2024.
  • 290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.